Details of Drug Interaction

Details of Drug-Drug Interaction

 Drug General Information (ID: DDI3NXQ90J)
  Drug Name Botulinum toxin type A Drug Info Procyclidine Drug Info
  Drug Type Protein/peptide Small molecule
  Therapeutic Class Muscle Relaxants Antiparkinson Agents

 Mechanism of Botulinum toxin type A-Procyclidine Interaction (Severity Level: Moderate)
     Additive anticholinergic effects Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Botulinum toxin type A Procyclidine
      Mechanism Anticholinergic effects
Synaptosomal-associated protein 25  Inhibitor 		Anticholinergic effects
Muscarinic acetylcholine receptor  Antagonist
      Key Mechanism Factor 1
Factor Name Synaptosomal-associated protein 25
×
Structure Sequence
MAEDADMRNELEEMQRRADQLADESLESTRRMLQLVEESKDAGIRTLVMLDEQGEQLERIEEGMDQINKDMKEAEKNLTDLGKFCGLCVCPCNKLKSSDAYKKAWGNNQDGVVASQPARVVDEREQMAISGGFIRRVTNDARENEMDENLEQVSGIIGNLRHMALDMGNEIDTQNRQIDRIMEKADSNKTRIDEANQRATKMLGSG
Gene Name SNAP25
Uniprot ID SNP25_HUMAN
KEGG Pathway hsa:6616
Protein Family SNAP-25 family
Protein Function
t-SNARE involved in the molecular regulation of neurotransmitter release. May play an important role in the synaptic function of specific neuronal systems. Associates with proteins involved in vesicle docking and membrane fusion. Regulates plasma membrane recycling through its interaction with CENPF. Modulates the gating characteristics of the delayed rectifier voltage-dependent potassium channel KCNB1 in pancreatic beta cells.
    Click to Show/Hide
      Key Mechanism Factor 2
Factor Name Muscarinic acetylcholine receptor M Structure Sequence
Protein Family G-protein coupled receptor 1 family
Protein Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
    Click to Show/Hide
      Mechanism Description
  • Additive anticholinergic effects by the combination of Botulinum toxin type A and Procyclidine 

Recommended Action
      Management Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.g., sedating antihistamines antispasmodics neuroleptics phenothiazines skeletal muscle relaxants tricyclic antidepressants disopyramide) are used after administration of botulinum toxin.

References
1 Product Information. Botox (onabotulinumtoxin A). Allergan Inc, Irvine, CA.
2 Product Information. Myobloc (botulinum toxin type B) Elan Pharmaceuticals, S. San Francisco, CA.
3 Product Information. Xeomin (botulinum toxin type A (obsolete) (botulinum toxin type A)). Merz Pharmaceuticals, Greensboro, NC.